Skip to main content
Premium Trial:

Request an Annual Quote

Corrected Reports

Blood-testing firm Theranos has voided two years' worth of results obtained using its Edison platform and has sent tens of thousands of corrected reports to doctors and patients, the Wall Street Journal reports.

This move, the Journal adds, comes after federal regulators uncovered a number of deficiencies at the company's California lab during an inspection and then, after finding the company's plan of corrective action lacking, threatened to bar CEO Elizabeth Holmes and president Sunny Balwani from owning or operating any lab for two years. Balwani stepped down last week.

The company now has informed regulators at the Centers for Medicare & Medicaid Services that it threw out all Edison-based results from 2014 and 2015, and the Journal notes that a number of physicians in the Phoenix area confirmed receiving voided or revised reports from Theranos.

"Excellence in quality and patient safety is our top priority and we've taken comprehensive corrective measures to address the issues CMS raised in their observations," Theranos spokesperson Brooke Buchanan tells the WSJ. "As these matters are currently under review, we have no further comment at this time."

One physician tells the paper that a revised report she received was for a patient whose initial Theranos test indicated an abnormal result, so much so that she sent the patient to the emergency room. The new report places the patient in the normal range.

Some of the revised results also came from tests run on platforms other than Edison, the Journal adds. A source tells the WSJ that a traditional lab machine from Siemens had been set incorrectly by Theranos and that Theranos didn't take the purity of the water used in the machines into account, as it should.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.